# Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

> **NCT04360486** · — · NO_LONGER_AVAILABLE · sponsor: **U.S. Army Medical Research and Development Command**

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2

## Interventions

- **BIOLOGICAL:** Anti-Sars-CoV-2 Convalescent Plasma

## Key facts

- **NCT ID:** NCT04360486
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360486, "Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04360486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*